The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Colorectal Cancer MORE >>

In an interview with Targeted Therapies in Oncology, Michael Cusnir, MD, explained that Y-90 is a type of beta emitter that is extremely focused, which allows for the treatment to be localized without affecting healthy portions of the liver or other structures surrounding the liver; it is delivered to selectively embolize the liver.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.